These medications are classified as pregnancy class C, indicating that animal studies suggest potential risks such as fetal growth restriction and congenital anomalies due to their ability to cross the placenta
Intensive Behavioral Therapy for Obesity opens in new window , Medicare.gov, last accessed April 24, 2026
Primary Endpoint: Weight Loss at 72 Weeks The results were striking and clinically significant: Zepbound Group: Participants achieved an average weight reduction of 20.2% at 72 weeks Wegovy Group: Participants achieved an average weight reduction of 13.7% at 72 weeks Relative Difference: Zepbound provided 47% greater relative weight loss compared to Wegovy To put this in practical terms: A patient weighing 250 pounds could expect to lose approximately 50 pounds with Zepbound versus 34 pounds with Wegovy over the same timeframe
When administered intranasally, melanotan is absorbed via the nasal mucosa into the bloodstream, where it interacts with melanocortin receptors
People who sleep well often report fewer cravings, steadier appetite control, and better energy during the day
The approvals are based on robust clinical trial data demonstrating their efficacy and safety with indications typically targeting a specific BMI category ( Figure 1 Orlistat, the earliest approved anti-obesity medication, remains available (Brand name Xenical produced by Roche
